Rationale

Incidence and prevalence of problem wounds

Problem wounds represent a significant and growing challenge to our healthcare system. The incidence and prevalence of these wounds are increasing in the population resulting in growing utilization of healthcare resources and dollars expended. Venous leg ulcers represent the most common lower extremity wound seen in ambulatory wound care centers with recurrences frequent and outcomes often less than satisfactory. Pressure ulcers are common in patients in long term institutional care settings adding significant increases in cost, disability, and liability. Foot ulcers in patients with diabetes contribute to over half of lower extremity amputations in the United States in a group at risk representing only 3 per cent of the population (1). In response to this challenge specialized programs have emerged designed to identify and manage these patients using a variety of new technology to improve outcomes. Hyperbaric oxygen treatment has been increasingly utilized in an adjunctive role in many of these patients coinciding with optimized patient and local wound care.

Hypoxia in wound healing failure

Normal wound healing proceeds through an orderly sequence of steps involving control of contamination and infection, resolution of inflammation, regeneration of the connective tissue matrix, angiogenesis, and resurfacing. Several of these steps are critically dependent upon adequate perfusion and oxygen availability. The end result of this process is sustained restoration of anatomical continuity and functional integrity. Problem or chronic wounds are wounds that have failed to proceed through this orderly sequence of events and have failed to establish a sustained anatomic and functional result (2). This failure of wound healing is usually the result of one or more local wound or systemic host factors inhibiting the normal tissue response to injury. These factors include persistent infection, malperfusion and hypoxia, cellular failure, and unrelieved pressure or recurrent trauma.

The hypoxic nature of all wounds has been demonstrated (3), and the hypoxia, when pathologically increased, has correlated with impaired wound healing (4) and increased rates of wound infection. Local oxygen tensions in the vicinity of the wound are approximately half the values observed in normal, non-wounded tissue (5,6,7). The rate at which normal wounds heal has been shown to be oxygen dependent. Fibroblast replication, collagen deposition (8), angiogenesis (9,10,11), resistance to infection (12,13), and intracellular leukocyte bacterial killing (14,15) are oxygen sensitive responses essential to normal wound healing. However, if the periwound tissue is normally perfused, steep oxygen gradients from the periphery to the hypoxic wound center support a normal wound healing response. (16,17)

Measurement of wound hypoxia

Transcutaneous oxygen tension (PtcO2) measurements provide a direct, quantitative assessment of oxygen availability to the periwound skin and an indirect measurement of periwound microcirculatory blood flow. The application of PtcO2 measurement in the assessment of peripheral vascular disease has been well described by
Scheffler (18) and its application to wound healing problems by Sheffield (19,20). This technology allows objective
determination of the presence and degree of local, periwound hypoxia serving as a screening tool to identify patients at
risk for failure of primary wound or amputation flap healing. It can also be used during assessment of patients with
lower extremity wounds as a screening tool for occult peripheral arterial occlusive disease.

PtcO2 measurements are made by applying a Clark polarographic electrode on the prepared surface of the
skin. A constant voltage is applied to the cathode that reduces oxygen molecules that have diffused from the superficial
dermal capillary plexus through the epidermis, stratum corneum, and electrode membrane generating a current that can
be measured and converted to a value representing the partial pressure of oxygen in mmHg. The electrode heats the
surface of the skin to 43 to 45°C to increase cutaneous blood flow, skin permeability, and oxygen diffusion. The
electrode is typically about 0.3mm from the capillary network in normal skin (21). PtcO2 is non-linear with respect to
blood flow exhibiting a hyperbolic response to changes in blood flow that is more pronounced as flow rates decrease
(18). PtcO2 is a more accurate reflection of changes in perfusion than is measurement of ankle brachial index (22).

Although there is some variability in PtcO2 values obtained based upon the type of electrode and temperature
used, in general, values below 25-40 mmHg have been associated with poor healing of wound and amputation flaps
with the lower the value the greater the degree of healing impairment. Multiple studies (22-31) have demonstrated that
PtcO2 values are a better predictor of flap healing success or failure following amputation or revascularization procedures
than arterial Doppler studies or clinical assessment, particularly in patients with diabetic foot ulcers (32-33). The addition of
provocative testing with lower extremity elevation or dependency (34,35) or following occlusion induced ischemia and
recovery (36) or with 100% oxygen breathing (37) may increase the sensitivity of the test as a screening tool for detecting
occult lower extremity arterial insufficiency.

Breathing 100% oxygen at 1 ATA or under hyperbaric conditions can improve the accuracy of PtcO2
measurement in predicting successful healing with adjunctive hyperbaric oxygen treatment. The following conclusions
were drawn from a study of 1144 diabetic foot ulcer patients who underwent adjunctive hyperbaric oxygen treatment in
support of wound healing or limb salvage (38). PtcO2 measured on air at sea level defines the degree of periwound hypoxia but has almost no value in predicting benefit with subsequent hyperbaric oxygen treatment. These measurements are more useful in predicting who will fail to heal without hyperbaric oxygen treatment. PtcO2 values below 35 mmHg obtained while breathing 100% oxygen at sea level are associated with a 41% failure rate of subsequent hyperbaric oxygen treatment while values obtained greater than 35 mmHg were associated with a 69% likelihood of a beneficial response. PtcO2 values measured during hyperbaric oxygen treatment exceeding a cutoff value of 200 mmHg were 74% reliable in predicting wound healing improvement or limb salvage as the result of a therapeutic course if hyperbaric oxygen. This positive predictive value is consistent with those reported by others in both arterial insufficiency and diabetic lower extremity wounds (39-41).

When evaluating problem chronic or acute wounds where local hypoxia is suspected to play a role in wound
healing failure, baseline PtcO2 measurements should be made breathing sea level air to define the presence and
degree of periwound hypoxia. Provocative testing with 30 degree elevation of the lower extremities may enhance the
sensitivity of testing to identify occult peripheral vascular disease (34,35). If hypoxia is identified, PtcO2 measurement
made while breathing 100% oxygen at sea level or preferably 100% oxygen during hyperbaric oxygen treatment may
indicate who is likely to respond successfully to treatment. Testing can also be repeated following lower extremity
angioplasty or revascularization to assess the physiological benefit of such interventions.

The laboratory evidence for hypoxia playing a major role in wound healing failure is not in dispute and has been
discussed above. Clinical studies identifying the risks of wound or amputation flap healing failure (42) define periwound
hypoxia as a primary determinant of future healing failure. In clinical practice, hyperbaric medicine physicians routinely
measure transcutaneous PO2 and use the information obtained to make patient selection and treatment decisions.
Unfortunately, however, the clinical trials and case series described below have not used measured periwound hypoxia
as a specific patient selection criterion. Unfortunately there is a lack of direct clinical trial data linking periwound
hypoxia as a selection criteria for hyperbaric oxygen and demonstrating the contribution of hyperbaric oxygen treatment
to improved outcome in these circumstances. Independent evidenced-based reviews of hyperbaric oxygen treatment in
problem wounds (43,44) have been unable to define a “hypoxic wound” as a specific wound category. Instead these
reviews have endorsed treatment of specific wound types such as diabetic foot ulcers, acute traumatic ischemic
injuries, radiation tissue injury, and compromised grafts and flaps among others.
Physiology of hyperbaric oxygenation of wounds

Regardless of the primary etiology of problem wounds, a basic pathway to non-healing is the interplay between tissue hypoperfusion, resulting hypoxia, and infection. A large body of evidence exists which demonstrates that intermittent oxygenation of hypoperfused wound beds, a process only achievable in selected patients by exposing them to hyperbaric oxygen treatment, mitigates many of these impediments and sets into motion a cascade of events that leads to wound healing. Hyperbaric oxygenation is achieved when a patient breathes 100% oxygen at an elevated atmospheric pressure. Physiologically, this produces a directly proportional increase in the plasma volume fraction of transported oxygen that is readily available for cellular metabolism. Arterial PO$_2$ elevations to 1500 mmHg or greater are achieved with 2 to 2.5 atm abs with soft tissue and muscle PO$_2$ levels elevated correspondingly. Oxygen diffusion varies in a direct linear relationship to the increased partial pressure of oxygen present in the circulating plasma caused by hyperbaric oxygen therapy. This significant level of hyperoxygenation allows for the reversal of localized tissue hypoxia, which may be secondary to ischemia or to other local factors within the compromised tissue.

In the hypoxic wound, hyperbaric oxygen therapy acutely corrects the pathophysiology related to oxygen deficiency and impaired wound healing. A key factor in hyperbaric oxygen therapy's enhancement of the hypoxic wound environment is its ability to establish adequate oxygen availability within the vascularized connective tissue compartment that surrounds the wound. Proper oxygenation of the vascularized connective tissue compartment is crucial to the efficient initiation of the wound repair process and becomes an important rate-limiting factor for the cellular functions associated with several aspects of wound healing. Neutrophils, fibroblasts, macrophages, and osteoclasts are all dependent upon an environment in which oxygen is not deficient in order to carry out their specific inflammatory or repair functions. Two groups of induced responses occur:

1) Improved leukocyte function of bacterial killing (45-46), antibiotic potentiation (48,49), and enhanced collagen synthesis (8) occur during periods of elevated tissue PO$_2$.
2) Suppression of bacterial toxin synthesis (50), blunting of systemic inflammatory responses (51), and prevention of leukocyte activation and adhesion following ischemic reperfusion (52-54) are effects that may persist even after completion of hyperbaric oxygen treatment.

In addition, vascular endothelial growth factor (VEGF) release is stimulated (55) and platelet derived growth factor (PDGF) receptor appearance (56-58) is also induced. The net result of serial hyperbaric oxygen exposures is improved local host immune response, clearance of infection, enhanced tissue growth and angiogenesis (59) with progressive improvement in local tissue oxygenation, and epithelialization of hypoxic wounds.

Diabetic Lower Extremity Wounds, the Prototype Hypoxic Wound

Lower extremity ulcers and amputations are an increasing problem for people with diabetes. Up to 6 per cent of all hospitalizations for diabetics include a lower extremity ulcer as a discharge diagnosis. When present, an ulcer increased hospital length of stay by an average of 59% compared to diabetics admitted without lower extremity ulcers. Finally, once an amputation occurs, nine to 20% of diabetic patients will experience an ipsilateral or contralateral amputation within 12 months and 28-52% within five years (1). The cost of care for a new diabetic foot ulcer has been calculated to be $27,987 in the two years following diagnosis (60).

The pathophysiology of diabetic foot ulceration, faulty healing, and lower extremity limb loss has been well described (42,61,62). It involves the progressive development of a sensory, motor, and autonomic neuropathy leading to loss of protective sensation, deformity increasing plantar foot pressures, and alternations in autoregulation of dermal blood flow. Diabetics show earlier development and progression of lower extremity peripheral arterial occlusive disease with a predilection for the trifurcation level vessels just distal to the knee. Impaired host immune response to infection and possible cellular dysfunction all contribute to the clinical outcomes described above.

Management, likewise, has been extensively described (63-66) and includes careful attention to identification and management of infection, aggressive surgical debridement, evaluation and correction of vascular insufficiency ambulatory off-loading, and glycemic control (67,68). While a full discussion of these interventions is beyond the scope of this review, they form the basis of effective diabetic foot ulcer management and must be applied consistently if adjunctive interventions are to provide an additive value. Other interventions have recently been advocated including topical application of a recombinant human platelet derived growth factor (PDGF-BB, becaplermin) (69), bioengineered human mono layer fibroblast grafts (70-72) and bi-layer fibroblast and keratinocyte (73,74) grafts, and negative
pressure wound therapy (wound vac) (75,76). Clearly, regardless of the interventions applied, limb salvage rates improve when care is applied in a multidisciplinary setting using comprehensive protocols for care (77).

Local wound hypoxia plays a pivotal role in diabetic wound healing failure and limb loss as evidenced by the report by Pecoraro (42) that when periwound PtcO2 values were below 20 mmHg they were associated with a 39 fold increased risk of primary healing failure. While aggressive distal lower extremity bypass grafting and lower extremity angioplasty have contributed to increased wound healing and limb salvage rates, technical grafting success does not necessarily equate with limb salvage. Hyperbaric oxygen treatment offers an intriguing opportunity to maximize oxygen delivery in the setting of minimal or insufficiently corrected blood flow.

**Clinical Experience with Hyperbaric Oxygen Treatment in Diabetic Lower Extremity Wounds**

Since 1999 there have been eight published independent evidence-based reviews that have addressed the effectiveness of hyperbaric oxygen treatment in problem, chronic wounds. These reviews have evaluated the results of:

1) Four randomized controlled clinical trials of hyperbaric oxygen treatment in diabetic lower extremity wounds (Table 1).
2) Two randomized controlled trials in non diabetic leg ulcers or where wound healing was not the outcome indicator (Table 2).
3) Two non-randomized controlled trials in diabetic lower extremity wounds (Table 3).
4) One prospective case series of hyperbaric oxygen treatment and infrapopliteal angioplasty in diabetic lower extremity wounds (Table 4).
5) Eight prospective or retrospective uncontrolled case series in diabetic lower extremity wounds (Table 5).

In the controlled trials, 334 patients were included in the hyperbaric oxygen treatment arms and 582 patients in the control arms. In the cases series, 1590 patients were reported. There were additional small retrospective series that were not included in this review.

In general, while specific selection criteria for inclusion for hyperbaric oxygen treatment were not provided, inference from the description of patients included can be made that most were Wagner grade (Table 5) III or greater ulcers since “diabetic gangrene” was frequently mentioned as a descriptor of patients included. Hypoxic transcutaneous PO2 values were not mentioned as an inclusion criterion for selection for the randomized controlled clinical trials.

The 1999 Blue Cross Blue Shield Technology Assessment (BCBS) (78) and the 2000 Australian Medicare Service Advisory Committee review (MSAC) (79) concluded that there was sufficient evidence to support the use of hyperbaric oxygen therapy in chronic non-healing wounds (BCBS) and diabetic wounds (MSAC). The April 7-8, 1999 Consensus Development Conference on Diabetic Foot Wound Care sponsored by the American Diabetes Association (64) concluded that “it is reasonable...to use this modality to treat severe and limb- or life threatening wounds that have not responded to other treatments, particularly if ischemia that cannot be corrected by vascular procedures is present.” The Wound Healing Society Provision Guidelines for Chronic Wound Care, June 21, 1999, Arterial Subcommittee (80) stated that...“in communities where accessible, hyperbaric oxygen treatment should be considered standard of care for wounds that are hypoxic (due to ischemia), and the hypoxia is reversible by hyperbaric oxygenation. The tissue hypoxia, reversibility, and responsiveness to oxygen challenge are measurable by transcutaneous oximetry.” The British Journal of Medicine, Clinical Evidence review (81) categorized hyperbaric oxygen treatment as "for diabetic foot ulcer, likely to be beneficial...limited evidence from two small randomized clinical trials suggests that systemic hyperbaric oxygen reduces the risk of foot amputation in people with severe infected foot ulcers. Two small randomized clinical trials have found that, compared with routine care, systemic hyperbaric oxygen reduces the risk of foot amputation in people with severe infected foot ulcers.”

In 2001, at the request of the Center for Medicare and Medicaid Services, reviewers from the New England Medical Center under contract with the Agency for Healthcare Research and Quality released a report (43,82) that concluded that “hyperbaric oxygen treatment aids in the healing of chronic non-healing wounds.” However, they also stated that “direct evidence on non-diabetic chronic non-healing wounds was not sufficient.” It appears that this conclusion was based on the observation that the majority of clinical trials involved diabetic lower extremity wounds.
The randomized controlled clinical trial of hyperbaric oxygen treatment in chronic diabetic lower extremity wounds reported by Doctor, et al (85) involved 30 patients randomized into treatment and control groups. Patients in the hyperbaric oxygen treatment group received only four treatments over a two week period. The treatment group had fewer major amputations (HBO 2/15 vs control 7/15) that was a statistically significant difference (p<0.05). There were also fewer repeat positive cultures in the treatment group (p=0.05).

Faglia, et al (86) reported a randomized controlled clinical trial of hyperbaric oxygen treatment for severe, hospitalized diabetic foot ulcer patients. Seventy consecutively admitted patients were enrolled in the study with 35 completing in the hyperbaric oxygen treatment group and 33 in the control group. All patients underwent a standard evaluation protocol, initial radical surgical debridement, weekly wound cultures with culture specific systemic antibiotic therapy, standardized wound care, and optimized metabolic control. All patients received a vascular evaluation and underwent arteriography if screening ankle-brachial index was <0.9 or PtcO2 < 50 mmHg and underwent angioplasty or revascularization if indicated. Hyperbaric oxygen treatment was administered daily at 2.4 ATA for 90 minutes after an initial treatment at 2.5 ATA for 90 minutes. The decision to perform a major amputation was performed by a consultant surgeon unaware of the treatment status. The treatment group underwent fewer major amputations (HBO 3/35 [8.6%] including 2 BKA and 1 AKA; control 11/33 [33.3%] including 7 BKA, 4 AKA). This difference was statistically significant (p=0.016). In a multivariate analysis, the authors concluded that hyperbaric oxygen treatment conferred a protective benefit with an odds ratio of 0.084 (p=0.033, 95% CI 0.008-0.821).

Abidia, et al (87) reported a randomized placebo controlled clinical trial that involved 33 patients. Each group received either 30 hyperbaric oxygen treatments for 90 minutes each or 30 sham treatments. At 12 weeks more patients in the hyperbaric oxygen treatment groups were healed (HBO 13/19, 68%; control 4/14, 29%) but no statistical analysis was given.

Kalani, et al. (88) reported a combined randomized and non-randomized controlled clinical trial of hyperbaric oxygen treatment in diabetic foot ulcers involving 38 patients. Seventeen patients received hyperbaric oxygen treatment and 21 were in the control group. The first 14 patients were randomly allocated (7 in each group), but the study was interrupted for two years and the final 24 patients were assigned to treatment or control groups in a non-randomized manner based on the availability of hyperbaric oxygen treatment. All patients underwent a baseline vascular evaluation but none were deemed eligible for revascularization. The treatment group received between 40-60 hyperbaric oxygen treatments at 2.4 ATA for 90 minutes five days per week. At the three year follow up point, more patients in the treatment group were healed (HBO 12/17 [76%]; control 2/17 [12%]) which was not statistically evaluated. Major amputations were also less frequent in the treatment group (2/17 [12%]; control 7/21[33%]).

In a retrospective multi center case series Fife, et al (38) reported the following outcomes with hyperbaric oxygen treatment in 1144 patients of whom final outcomes could be determined in all but 68 cases. All patients had hypoxic initial PtcO2 values recorded prior to initiation of adjunctive hyperbaric oxygen treatment. Overall, 75.6% of those in whom a Wagner score was available had a positive response to treatment. Table 6. demonstrates the response rate within each Wagner score grouping. These outcomes are superior to other clinical trials or case series reported of similar Wagner score patients. In the becaplermin clinical trials (69) ulcers with significant hypoxia (PtcO2 values less than 30 mmHg) and osteomyelitis (Wagner III) were excluded, and healing rates of only 46.7% were achieved.

In summary, the available evidence supports classifying the use of adjunctive in hyperbaric oxygen treatment for diabetic foot ulcers meets the requirements for AHA Class I definitely recommended based on Level A evidence of positive randomized controlled trials with statistically positive results. In the broader category of hypoxic wounds, based on the absence of trials using measured tissue hypoxia as a patient inclusion criterion, adjunctive hyperbaric oxygen treatment meets the requirements for AHA Class IIb acceptable and useful with fair to good evidence for support based upon limited level clinical trial data but with substantial level B non-randomized retrospective case series where PtcO2 values were reported but not used for inclusion, animal models with very reasonable extrapolations from existing data, and rational conjecture and historical acceptance. Randomized clinical trials should be performed to better define a “hypoxic” wound as a unique wound category and the value of hyperbaric oxygen treatment in this setting.

On August 30, 2002, the Center for Medicare and Medicaid Services announced in CAG-00060N, Coverage Decision Memorandum for Hyperbaric Oxygen Therapy in the Treatment of Hypoxic Wounds and Diabetic Wounds of the Lower Extremities (44) and in Transmittal AB-02-183 Program Memorandum for Intermediaries/Carriers its decision
to cover treatment of diabetic wounds of the lower extremities with hyperbaric oxygen effective April 1, 2003, in patients meeting the following criteria:

1. Patient has type 1 or 2 diabetes and has a lower extremity wound that is due to diabetes;
2. Patient has a wound classified as Wagner grade (Table 5) III or higher (81,82);
3. Patient has failed an adequate course of standard wound therapy (defined as 30 days of standard treatment including assessment and correction of vascular abnormalities, optimization of nutritional status and glucose control, debridement, moist wound dressing, off-loading, and treatment of infection).

For treatment to continue, re-evaluations at 30-day intervals must show continued progress to healing.

Other Potentially Hypoxic Wounds

Venous Stasis Ulcers

Compression therapy with multilayer external compression bandaging techniques remains the mainstay of management of venous stasis ulcers of the lower extremity (89,90). Recent evidence suggests that bioengineered tissue grafts (91) used in combination with standard compression bandaging techniques may shorten time to healing. While one prospective, blinded, randomized clinical trial of hyperbaric oxygen treatment in leg ulcers of undefined etiology (92) showed a statistically greater reduction in wound size at six weeks compared to control wounds, hyperbaric oxygen treatment is not indicated in the primary management of venous stasis ulcers of the lower extremities. Hyperbaric oxygen may be required to support skin grafting in patients with concomitant peripheral arterial occlusive disease and hypoxia not corrected by control of edema.

Pressure Ulcers

The management of decubitus ulcers has been well described elsewhere (93) and emphasizes pressure relief, surgical debridement, treatment of infection, nutritional support, and surgical closure for large ulcers. Other interventions such as negative pressure wound therapy (wound vac) may be beneficial. Hyperbaric oxygen treatment is not indicated in routine decubitus ulcer management. It may be necessary for support of skin grafts or flaps showing evidence of ischemic failure, when the ulcer develops in the field of previous radiation treatment for pelvic or perineal malignancies, or when progressive necrotizing soft tissue infection or refractory osteomyelitis is present.

Arterial Insufficiency Ulcers

The primary treatment of refractory ischemic wounds of the lower extremities is improvement in blood flow by angioplasty or surgical revascularization. However, hyperbaric oxygen treatment may be of benefit in those cases where persistent hypoxia remains after attempts at increasing blood flow or when wound failure continues despite maximum revascularization (80). Hyperbaric oxygen treatment may also be required in support of skin grafting in this setting (94).

Hyperbaric Oxygen Treatment Protocols

Treatment protocols vary depending on the severity of the problem and the type of hyperbaric chamber used. In larger multiplace chambers, treatments are delivered at 2.0 to 2.5 ATA for 90 to 120 minutes once or twice daily. In monoplace chambers patients are usually treated at 2.0 ATA. Patients with serious infections may require hospitalization for intravenous antibiotics and better diabetes control. Hyperbaric oxygen treatment in such cases is usually rendered twice daily for 90 minutes. Once stabilized most of these patients can be treated on a once daily basis as outpatients. When infection is controlled, blood flow optimized (wherever possible), other interventions that may hasten tissue growth and wound closure such as negative pressure wound therapy (wound vac), bioengineered tissue grafts, or surgical reconstruction or closure can be used in combination with adjunctive hyperbaric oxygen treatment to hasten recovery. The October 2000 Office of the Inspector General report to the Department of Health and Human Services (95) identified that active physician oversight of hyperbaric oxygen treatment led to improved outcomes.
Utilization Review

Hyperbaric oxygen treatments are performed at 2.0 to 2.5 ATA for 90 to 120 minutes of oxygen breathing. The initial treatment schedule is dictated by the severity of the disease process. In the presence of limb-threatening infection after debridement or incompletely corrected peripheral arterial occlusive disease, patients may require twice daily treatments. Once stabilized, treatment frequency may decrease to once daily. Utilization review is required after the initial 30 days of treatment and at least that frequently thereafter.

Cost Impact

Hyperbaric oxygen therapy as an adjunct to medical and surgical treatment of difficult problem, chronic wounds, particularly diabetic lower extremity wounds, has been shown to be cost effective in limited reviews, especially when compared to major lower extremity amputation (96,97). Preventing a below the knee amputation by salvaging a ray resection or transmetatarsal amputation of the foot or preventing an above the knee amputation by preserving a below the knee amputation represents a satisfactory outcome in these high risk patients. Wounds healed with adjunctive hyperbaric oxygen treatment have also demonstrated excellent durability (98).

Tables

Table 1. Randomized Controlled Trials of HBO in DFU

<table>
<thead>
<tr>
<th>Author Year, Country</th>
<th>Study Design</th>
<th>N</th>
<th>Condition</th>
<th>PtcO2 Recorded</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doctor (85) 1992, India</td>
<td>RCT</td>
<td>30 (15 HBO, 15 control)</td>
<td>Hospitalized DFU</td>
<td>N</td>
<td>Above ankle amputations: HBO 2/15, Control: 7/15  P&lt;0.05; Minor amputations NS Number of + cultures decreased in HBO group P&lt;0.05</td>
</tr>
<tr>
<td>Faglia (86) 1996, Italy</td>
<td>RCT</td>
<td>70 (35 HBO, 33 control)</td>
<td>Severe infected DFU</td>
<td>Y*</td>
<td>Major amputations: HBO 3/35 (8.6%) Control 11/33 (33.3%)  P=0.016</td>
</tr>
<tr>
<td>Abidia (87) 2001, UK</td>
<td>RCT, placebo Abstract</td>
<td>33 (19 HBO, 14 control)</td>
<td>Diabetic leg ulcers</td>
<td>N</td>
<td>Healing at 12 week follow up point: HBO: 13/19 (68%), Control: 4/14 (29%); No difference in major amputation rates between groups</td>
</tr>
<tr>
<td>Kalani (88) 2002, Sweden</td>
<td>RCT + CT</td>
<td>38 (17 HBO, 21 control)</td>
<td>DFU</td>
<td>N</td>
<td>Healing at 3 year follow up point: HBO: 13/17 (76%), Control 10/21 (48%); Amputations: HBO: 2/17 (12%), Control 7/21 (33%)</td>
</tr>
</tbody>
</table>

Table 2. Randomized Controlled Trials of HBO in Non DFU or Where Wound Healing Not the Outcome

<table>
<thead>
<tr>
<th>Author Year, Country</th>
<th>Study Design</th>
<th>N</th>
<th>Condition</th>
<th>PtcO2 Recorded</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hammarlund (92) 1994, Sweden</td>
<td>RCT, DB, placebo</td>
<td>16 (8 HBO, 8 control)</td>
<td>Non diabetic leg ulcers</td>
<td>N</td>
<td>Mean wound surface area decreased at 6 week endpoint: HBO: 35.7% (+-17%), Control: 2.7% (+-11%)  P&lt;0.001</td>
</tr>
<tr>
<td>Lin (99) 200, Taiwan</td>
<td>RCT Abstract</td>
<td>29 (17 HBO, 12 control)</td>
<td>DM with Wagner 0,1,II</td>
<td>Y*</td>
<td>Improvement in vascular function: PtcO2 post 30 treatments HBO 57.5 +20.7 mmHg vs controls 35.8 +21.2 mmHg  P&lt;0.01</td>
</tr>
</tbody>
</table>

Table 3. Prospective Series HBO Combined with Distal Lower Extremity Angioplasty

<table>
<thead>
<tr>
<th>Author Year, Country</th>
<th>Study Design</th>
<th>N</th>
<th>Condition</th>
<th>PtcO2 Recorded</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanna (22) 1997, USA</td>
<td>Prospective consecutive uncontrolled series</td>
<td>29 infrapopl</td>
<td>DFU with severe PVD</td>
<td>Y*</td>
<td>PtcO2 &lt; 40mmHg associated with poor healing. PtcO2 changes better predictor of ultimate outcomes than ABI, at 6 months 23/29, 79%, had complete healing, 3/29 had failed</td>
</tr>
</tbody>
</table>
recannalizations with subsequent BKAs, 2/29 had BKAs despite successful recannalization due to persistent severe osteomyelitis, 1/29 expired from AMI with healing wound

### Table 4. Controlled Trials of HBO in DFU

<table>
<thead>
<tr>
<th>Author Year, Country</th>
<th>Study Design</th>
<th>N</th>
<th>Condition</th>
<th>Ptco2 Recorded</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zamboni (100) 1997, USA</td>
<td>CT</td>
<td>10 (5 HBO, 5 control)</td>
<td>DFU</td>
<td>Y*</td>
<td>HBO with standard wound care reduced wound size compared to standard wound care alone (5/168) compared to controls 1/5 (P&lt;0.05). At 4-6 months HBO group had higher rate of complete healing (4/5 compared to controls 1/5).</td>
</tr>
<tr>
<td>Baroni (101) 1987, Italy</td>
<td>CT</td>
<td>28 (18 HBO, 10 control)</td>
<td>DFU</td>
<td>N</td>
<td>Healing: HBO: 16/18 (89%), Control: 1/10 (10%) (P=0.001). Amputations: HBO: 2/18, Control: 4/10.</td>
</tr>
</tbody>
</table>

### Table 5. Prospective/Retrospective Uncontrolled Series of HBO in DFU

<table>
<thead>
<tr>
<th>Author Year, Country</th>
<th>Study Design</th>
<th>N</th>
<th>Condition</th>
<th>Ptco2 Recorded</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis (102) 1987, USA</td>
<td>Retro review</td>
<td>168 HBO</td>
<td>DFU</td>
<td>N</td>
<td>118/168 (70%) patients healed at a level providing for bipedal ambulation, 50/168 (30%) required a BKA or AKA, failures in patients with non bypassable arterial disease at or above ankle.</td>
</tr>
<tr>
<td>Cianci (96) 1988, USA</td>
<td>Prospective consecutive no controls</td>
<td>39 HBO</td>
<td>Foot ulcers, 49% DFU, 51% other limb threatening, 41% prior bypass</td>
<td>N</td>
<td>Overall limb salvage rate (TMA or less) 35/39 (90%), diabetes and need for revascularization increased risk of failure (only 75% successful if diabetes and revascularization for limb threatening lesion), total hospital charges of $36,706.</td>
</tr>
<tr>
<td>Oriani (103) 1990, Italy</td>
<td>Retro comp</td>
<td>80 (62 HBO, 18 control)</td>
<td>DFU</td>
<td>N</td>
<td>&quot;Recovery&quot;: HBO: 59/62 (96%), Control: 12/18 (67%); Amputation: HBO: 3/62 (5%), 6/18 (33%) (P&lt;0.001).</td>
</tr>
<tr>
<td>Wattel (104) 1991, France</td>
<td>Retro consec review</td>
<td>59 HBO</td>
<td>DFU</td>
<td>Y*</td>
<td>52/59 (88%) healed without major amputation, 7/59 (12%) required major amputation, significantly higher PtcO2 values achieved during HBO (786 ±258mmHg vs 323 ±214) in success compared to failures.</td>
</tr>
<tr>
<td>Oriani (105) 1992, Italy</td>
<td>Retro consecutive review uncontrolled</td>
<td>151 HBO (may include patients from 1990 series)</td>
<td>DFU</td>
<td>N</td>
<td>130/151, 86% healed with HBO, 21/15, 14% failed with HBO.</td>
</tr>
<tr>
<td>Stone (106) 1995, USA</td>
<td>Retro review Abstract</td>
<td>469 (87 HBO, 382 control)</td>
<td>DFU</td>
<td>N</td>
<td>Limb salvage: HBO: 72%, Control: 53% (P&lt;0.002).</td>
</tr>
<tr>
<td>Faglia (107) 1998, Italy</td>
<td>Compare</td>
<td>115 (51 HBO, 64 control)</td>
<td>DFU</td>
<td>Y*</td>
<td>Major amputations: HBO: 7/51, Control: 20/64 (P=0.012.</td>
</tr>
<tr>
<td>Fife (38) 2002, USA</td>
<td>Retro review</td>
<td>1144 HBO</td>
<td>DFU</td>
<td>Y*</td>
<td>Overall 75% of patients improved with HBO, mean 34 treatments; By Wagner score: I: 100% (n=3), II: 83.1% (N=130), III: 77.2% (n=465), IV: 64.5% (n=64.5%), V: 29.7% (n=37).</td>
</tr>
</tbody>
</table>

*Ptco2 values recorded but not utilized as a criterion for inclusion.*
Table 5. Wagner Grading System for Diabetic Foot Ulcers

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Intact skin</td>
</tr>
<tr>
<td>I</td>
<td>Superficial without penetration deeper layers</td>
</tr>
<tr>
<td>II</td>
<td>Deeper reaching tendon, bone, or joint capsule</td>
</tr>
<tr>
<td>III</td>
<td>Deeper with abscess, osteomyelitis, or tendonitis extending to those structures</td>
</tr>
<tr>
<td>IV</td>
<td>Gangrene of some portion of the toe, toes, and/or forefoot</td>
</tr>
<tr>
<td>V</td>
<td>Gangrene involving the whole foot or enough of the foot that no local procedures are possible</td>
</tr>
</tbody>
</table>

Table 6. Wagner Score and HBO Outcome, Fife, et al. (38)

<table>
<thead>
<tr>
<th>Wagner Score</th>
<th>Sample Size</th>
<th>Percent Helped by HBO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>3</td>
<td>100.0</td>
</tr>
<tr>
<td>II</td>
<td>130</td>
<td>83.1</td>
</tr>
<tr>
<td>III</td>
<td>465</td>
<td>77.2</td>
</tr>
<tr>
<td>IV</td>
<td>138</td>
<td>64.5</td>
</tr>
<tr>
<td>V</td>
<td>37</td>
<td>29.7</td>
</tr>
</tbody>
</table>

References


50. VanUnnik AJM. Inhibition of toxin production in Clostridium perfringens in vitro by hyperbaric oxygen. Antonie Van Leeuwenhoek 1965;31:181-186.


78. Hyperbaric Oxygen Therapy for Wound Healing – Part I. Blue Cross Blue Shield Association TEC, Technology Assessment, August 1999. USA.


